Moreover, treatment of CD4+ T cells with mitochondrial metabolism inhibitors and glucose metabolism inhibitors reduced interferon-γ production and reversed disease biomarkers in lupus-prone mice [20]. This evidence concerns the gene CD4 and systemic lupus erythematosus.